Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Here’s the problem

<< Previous

Bullboard Posts

Next >>

Comment by postie1on Mar 10, 2020 8:23am

80 Views

Post# 30787353

RE:RE:RE:RE:RE:Here’s the problem

Bad timing is quite correct. Just hope that the problem can be solved.
For those who believe that cornstarch is a miracle drug and works wonders , I would think that you would be buying into companies like Ingredion. After all is said and done,I do not believe anyone should substitute their medicine with cornstarch.(Bakker included)

<< Previous

Bullboard Posts

Next >>

UniDoc brings AI-powered H3 Health Cube to Italy